• Coronary Heart Disease Risk Assessment and Treatment Strategies to Reduce Cardiovascular Events
  • CME

  • Coronary Heart Disease - Risk Assessment and Treatment Strategies to Reduce Cardiovascular Events

  • Author(s)/Faculty: Peter P. Toth, MD, PhD, FAAP, FNLA, FAHA, FACC; Michael H. Davidson, MD, FACC, FACP, FNLA; Alan S. Brown, MD
    Source: Endocrine Today
    Type: Monograph Articles/Items: 1
    Release Date: 8/1/2011 Expiration Date: 8/31/2012
    Credit Type: CME Number of Credit(s): 1.25
    Cost: Free Provider: Vindico Medical Education
  • Statins have had a significant effect on coronary heart disease risk since their introduction. However, a residual risk for cardiovascular events persists. In addition to lowering LDL levels, clinicians must be aware of how to manage patients with low HDL levels and high triglycerides. Statins may have an affect on these lipids as well. This monograph will review the impact of statins on lipid profiles, as well as potential adverse events and drug interactions. Strategies to improve statin safety and compliance will also be discussed.

Sponsorship Statement: This continuing education activity is sponsored by Vindico Medical Education.

Support Statement: This activity is supported by an educational grant from Kowa-Lilly

Target Audience: The intended audience for this activity is cardiologists, endocrinologists, lipidologists and other health care providers who treat dyslipidemia.

Learning Objectives: At the conclusion of this activity, participants should be able to:

  • Implement strategies for managing patients with statin intolerance and noncompliance, including pre-existing conditions associated with statin intolerance/noncompliance such as hypothyroidism, vitamin D deficiency, depression, and fibromyalgia.
  • Recognize the cardiovascular risk associated with low HDL-C even for patients on statin therapy and appreciate the differences between statins on HDL-C raising efficacy.
  • Improve confidence in the implementation of combination therapy for achievement of NCEP ATP LDL-C and non-HDL-C goals.
  • Apply the clinical trial evidence that support lipid-lowering use in primary prevention and recognize the potential treatment difference for patients based on age, gender, and cultural or ethnic differences.

Course Chair:
Michael H. Davidson, MD, FACC, FACP, FNLA
Clinical Professor of Medicine
Director of Preventive Cardiology
The University of Chicago, Pritzker School of Medicine
Executive Medical Director
Radiant Research
Chicago, IL

Faculty:
Alan S. Brown, MD, FACC
Interventional Cardiologist
Midwest Heart Specialists
Director, Midwest Heart Disease Prevention Center
Naperville, IL
Clinical Associate Professor of Medicine
Loyola Stritch School of Medicine
Loyola University Chicago
Chicago, IL

Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC
Director of Preventive Cardiology
Sterling Rock Falls Clinic, Ltd.
Sterling, IL
Professor of Clinical Family and Community Medicine
University of Illinois College of Medicine
Peoria, IL

Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, August 1, 2011 to August 31, 2012.

How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Planning Committee and Faculty:
Michael H. Davidson, MD, FACC, FACP, FNLA
Alan S. Brown, MD, FACC
Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC

External Reviewer:
Benjamin Ansell, MD

Medical Writer:
Valerie Zimmerman, PhD

Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Planning Committee and Faculty members report the following relationship(s):
Michael H. Davidson, MD, FACC, FACP, FNLA
Speakers’ Bureau: Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Merck
Advisory Board/Consultant: Abbott Laboratories, Aegerion, Amgen, AstraZeneca, Atherotech, Daiichi-Sankyo, DTC MD, Esperion, GlaxoSmithKline, iMD (Intelligent Medical Decisions), Kinemed, LipoScience, Merck, Novo Nordisk, Roche, Sanofi-aventis, Synarc, Takeda, Vindico Medical Education
Grant/Research: Abbott Laboratories, AstraZeneca, Daiichi-Sankyo, GlaxoSmithKline, Merck, Roche
Board of Directors: DTC MD, Omthera, Professional Evaluation Inc Medical Education Company, Sonogene

Alan S. Brown, MD, FACC
Fees for Non-CME Services: Abbott, Daiichi Sankyo, Forest, Merck, Schering Plough

Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC
Consulting Fees: Abbott Laboratories, Genentech, Genzyme, Kowa, Merck
Speakers’ Bureau: Abbott Laboratories, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Kowa, Merck, Takeda

External Reviewer reports the following relationship(s):
Benjamin Ansell, MD
Consulting Fees: Genentech, Ortho-Jansen
Fees for Non-CME Services: Pfizer
Ownership Interest (stocks, stock options, or other ownership interest excluding diversified mutual funds): Amgen, Biogen, Bruin Pharma

Medical Writer reports the following relationship(s):
Valerie Zimmerman, PhD
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2011 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.